Description

Tesamorelin Structure

Name: Tesamorelin; Egrifta
CAS No.: 901758-09-6
Peptide Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular Formula: C221H366N72O67S?C2H4O2
Molecular Weight: 5195.9
Appearance: White Lyophilized powder

Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group

Tesamorelin is used for Reducing excess stomach fat in certain HIV-infected patients.
Tesamorelin is a human growth hormone-releasing factor (GRF) analog. It works by stimulating the pituitary gland to release growth hormone (GH). This causes the breakdown of excess stomach fat.

Product use: This product is only for research chemicals.